medigraphic.com
ISSN 2395-8723 (Digital)
ISSN 1405-888X (Impreso)
TIP Revista Especializada en Ciencias Químico-Biológicas

2021, Número 1

<< Anterior Siguiente >>

TIP Rev Esp Cienc Quim Biol 2021; 24 (1)


Evaluación biológica in vitro e in silico de derivados de ftalamida como agentes antiproliferativos

Sierra-Rivera CA, Kashif M, Vázquez-Jiménez LK, Zugasti-Cruz A, Juárez-Saldivar A, Paz-González AD, Rivera G

Idioma: Ingles.
Referencias bibliográficas: 35
Paginas:
Archivo PDF: 985.86 Kb.


RESUMEN

La estructura de la ftalimida es considerada un bloque de construcción para el desarrollo de nuevos agentes anticancerígenos. En este trabajo, se evaluó la actividad antiproliferativa de cuarenta y tres derivados de ftalimida contra las líneas celulares cancerígenas de cérvix (HeLa), hígado (HepG2), mama (4T1), y la línea celular normal de fibroblastos murinos (3T3). Por último, se realizó un análisis de acoplamiento molecular de los derivados de la ftalimida en el sitio activo de la enzima metiltransferasa 1 de DNA (DNMT1, por sus siglas en inglés) y el receptor del factor de crecimiento endotelial vascular 2 (VEGR2, por sus siglas en inglés) como posibles blancos farmacológicos. Los compuestos C16, E11 y E16 mostraron la mejor actividad antiproliferativa contra las líneas celulares HeLa y 4T1. Solamente, el compuesto H16 disminuyó 32% la proliferación celular de la línea HepG2. Los compuestos H5, H16, E2, E16 y C1 no afectaron la proliferación celular de la línea 3T3. El análisis de acoplamiento molecular demostró que los derivados de la ftalimida tienen una mayor afinidad que la S-adenosil-l-homocisteína, un potente inhibidor de la metiltransferasa 1 de DNA. Sin embargo, los resultados del acoplamiento molecular no se correlacionan con los efectos antiproliferativos; lo cual sugiere que los compuestos activos tienen otro mecanismo de acción.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Abdelhaleem, E. F., Abdelhameid, M. K., Kassab, A. E. & Kandeel, M. M. (2018). Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. European Journal of Medicinal Chemistry, 143, 1807-1825. https://doi.org/10.1016/j.ejmech.2017.10.075

  2. Al-Abbasi, F. A., Alghamdi, E. A., Baghdadi, M. A., Alamoudi, A. J., El-Halawany, A. M., El-Bassossy, H. M., Aseeri, A. H. & Al-Abd, A. M. (2016). Gingerol Synergizes the Cytotoxic Effects of Doxorubicin against Liver Cancer Cells and Protects from Its Vascular Toxicity. Molecules, 21(7), 886. https://doi.org/10.3390/molecules21070886

  3. Aliabadi, A., Mohammadi-Farani, A., Hosseinzadeh, Z., Nadri, H., Moradi, A. & Ahmadi, F. (2015). Phthalimide analogs as probable 15-lipoxygenase-1 inhibitors: synthesis, biological evaluation and docking studies. Daru Journal of Pharmaceutical Sciences, 23(1), 36. https://doi. org/10.1186/s40199-015-0118-5

  4. Al-Soud, Y. A. & Al-Masoudi, N. A. (2001). Synthesis and antitumor activity of some new phthalimide analogues. Pharmazie, 56, 372-375. https://doi.org/10.1002/ CHIN.200132132

  5. Asgatay, S., Champion, C., Marloie, G., Drujon, T., Senamaud- Beaufort, C., Ceccaldi, A., Erdmann, A., Rajavelu, A., Schambel, P., Jeltsch, A., Lequin, O., Karoyan, P., Arimondo, P. B. & Guianvarc’h, D. (2014). Synthesis and evaluation of analogues of N-phthaloyl-L-tryptophan (RG108) as inhibitors of DNA methyltransferase 1. Journal of Medicinal Chemistry, 57, 421-434. https://doi.org/10.1021/jm401419p

  6. Bailly, C., Carrasco, C., Joubert, A., Bal, C., Wattez, N., Hildebrand, M.P., Lansiaux, A., Colson, P., Houssier, C., Cacho, M., Ramos, A. & Braña, M.F. (2003). Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono-and bisfuronaphthalimides. Biochemistry, 42, 4136-4150. https://doi.org/10.1021/ bi027415c

  7. Chen, Z., Liang, X., Zhang, H., Xie, H., Liu, J., Xu, Y., Zhu, W., Wang, Y., Wang, X., Tan, S., Kuang, D. & Qian, X. (2010). A new class of naphthalimide-based anti-tumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis. Journal of Medicinal Chemistry, 53, 2589-2600. https://doi. org/10.1021/jm100025u

  8. Grigalius, I. & Petrikaite, V. (2017). Relationship between Antioxidant and Anticancer Activity of Trihydroxyflavones. Molecules, 22, 2169. https://doi.org/10.3390/ molecules22122169

  9. Kamal, A., Reddy, B. S. N., Reddy, G. S. K. & Ramesh, G. (2002). Design and synthesis of C-8 linked pyrrolobenzodiazepinenaphthalimide hybrids as anti-tumour agents. Bioorganic and Medicinal Chemistry Letters, 12, 1933-1935. https:// doi.org/10.1016/S0960-894X(02)00326-8

  10. Kamal, A., Bolla, N. R., Srikanth, P. S. & Srivastava, A. K. (2013). Naphthalimide derivatives with therapeutic characteristics: a patent review. Expert Opinion on Therapeutic Patents, 23, 299-317. https://doi.org/10.1517/13543776.2013.746313

  11. Kashif, M., Chacón-Vargas, K. F., López-Cedillo, J. C., Nogueda-Torres, B., Paz-González, A. D., Ramírez- Moreno, E., Agusti, R., Uhrig, M. L., Reyes-Arellano, A., Peralta-Cruz, J., Ashfaq, M. & Rivera, G. (2018). Synthesis, molecular docking and biological evaluation of novel phthaloyl derivatives of 3-amino-3-aryl propionic acids as inhibitors of Trypanosoma cruzi trans-sialidase. European Journal of Medicinal Chemistry, 156, 252-268. https://doi. org/10.1016/j.ejmech.2018.07.005

  12. Kilic-Kurt, Z., Bakar-Ates, F., Karakas, B. & Kütük, Ö. (2018). Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d] Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines. Anticancer Agents in Medicinal Chemistry, 18, 1303-1312. https://doi.org/10.2174/1871520618666 180605082026

  13. Li, X., Lin, Y., Wang, Q., Yuan, Y., Zhang, H. & Qian, X. (2011). The novel anti-tumor agents of 4-triazol-1, 8- naphthalimides: synthesis, cytotoxicity, DNA intercalation and photocleavage. European Journal of Medicinal Chemistry, 46, 1274-1279. https://doi.org/10.1016/j. ejmech.2011.01.050

  14. Lu, G. Q., Li, X.Y., Mohamed, O. K., Wang, D. & Meng, F. H. (2019). Design, synthesis and biological evaluation of novel uracil derivatives bearing 1, 2, 3-triazole moiety as thymidylate synthase (TS) inhibitors and as potential antitumor drugs. European Journal of Medicinal Chemistry, 171, 282-296. https://doi.org/10.1016/j. ejmech.2019.03.047

  15. Mai, A. & Altucci, L. (2009). Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. International Journal of Biochemistry & Cell Biology, 41, 199-213. https://doi.org/10.1016/j.biocel.2008.08.020

  16. Matsuo, K. Lin, Y. G., Roman, L. D. & Sood A. K. (2010). Overcoming platinum resistance in ovarian carcinoma. Expert Opinion on Investigational Drugs, 19, 1339-54. https://doi.org/10.1517/13543784.2010.515585

  17. Miyachi, H., Ogasawara, A., Azuma, A. & Hashimoto, Y. (1997). Tumor necrosis factor-alpha production-inhibiting activity of phthalimide analogues on human leukemia THP-1 cells and a structure-activity relationship study. Bioorganic & Medicinal Chemistry, 5, 2095-2102. https:// doi.org/10.1016/S0968-0896(97)00148-X

  18. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S. & Olson A. J. (2009). Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. Journal of Computational Chemistry, 16, 2785-2791. https://doi.org/10.1002/jcc.21256

  19. O’Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T. & Hutchison, G. R. (2011). Open Babel: An open chemical toolbox. Journal of Cheminformatics, 3, 33. https://doi.org/10.1186/1758-2946-3-33

  20. Olazarán-Santibáñez, F., Bandyopadhyay, D., Carranza- Rosales, P., Rivera, G. & Balderas-Rentería, I. (2017a). Stereochemical preference toward oncotarget: Design, synthesis and in vitro anticancer evaluation of diastereomeric β-lactams. Oncotarget, 8, 37773-37782. https://doi. org/10.18632/oncotarget.18077

  21. Olazarán, F. E., Rivera, G., Pérez-Vázquez, A. M., Morales- Reyes, C.M., Segura-Cabrera, A. & Balderas-Rentería, I. (2017b). Biological Evaluation in vitro and in silico of Azetidin-2-one Derivatives as Potential Anticancer Agents. ACS Medicinal Chemistry Letters, 8, 32-37. https://doi. org/10.1021/acsmedchemlett.6b00313

  22. Othman, I. M. M., Gad-Elkareem, M. A. M., El-Naggar, M., Nossier, E. S. & Amr, A. E. E. (2019). Novel phthalimide based analogues: design, synthesis, biological evaluation, and molecular docking studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 34(1), 1259-1270. https://doi. org/10.1016/j.bioorg.2019.102978

  23. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C. & Ferrin, T. E. (2004). UCSF Chimera--a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25, 1605-1612. https://doi.org/10.1002/jcc.20084

  24. Philoppes, J. N. & Lamie, P. F. (2019). Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents. Bioorganic Chemistry, 89, 102978. https://doi.org/10.1016/j.bioorg.2019.102978

  25. Rivera, G., Ahmad-Shah, S. S., Arrieta-Baez, D., Palos, I., Mongue, A. & Sánchez-Torres, L. E. (2017a). Esters of Quinoxaline 1,4-Di-N-oxide with Cytotoxic Activity on Tumor Cell Lines Based on NCI-60 Panel. Iranian Journal of Pharmaceutical Research, 16, 953-965. https://dx.doi. org/10.22037/ijpr.2017.2065

  26. Rivera, G., Andrade-Ochoa, S., Romero, M. S. O., Palos, I., Monge, A. & Sanchez-Torres, L. E. (2017b). Ester of Quinoxaline-7-carboxylate 1,4-di-N-oxide as Apoptosis Inductors in K-562 Cell Line: An in vitro, QSAR and DFT Study. Anticancer Agents in Medicinal Chemistry, 17, 682-691. https://doi.org/10.2174/187152061666616 0630175927

  27. Salentin, S., Schreiber, S., Haupt, V. J., Adasme, M. F. & Schroeder, M. (2015). PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Research, 43, W443-447. https://dx.doi.org/10.1093/nar/gkv315

  28. Shiheido, H., Terada, F., Tabata, N., Hayakawa, I., Matsumura, N., Takashima, H., Ogawa, Y., Du, W., Yamada, T., Shoji, M., Sugai, T., Doi, N., Iijima, S., Hattori, Y. & Yanagawa, H. (2012). A phthalimide derivative that inhibits centrosomal clustering is effective on multiple myeloma. PLoS One, 7, e38878. https://doi.org/10.1371/journal.pone.0038878

  29. Siedlecki, P, Garcia Boy, R, Musch, T, Brueckner, B, Suhai, S, Lyko, F. & Zielenkiewicz, P. (2006). Discovery of two novel, small-molecule inhibitors of DNA methylation. Journal of Medicinal Chemistry, 49(2), 678-683. https:// doi.org/10.1021/jm050844z

  30. Sundaresan, L., Kumar, P., Manivannan, J., Balaguru, U. M., Kasiviswanathan, D., Veeriah, V., Anishetty, S. & Chatterjee, S. (2019). Thalidomide and Its Analogs Differentially Target Fibroblast Growth Factor Receptors: Thalidomide Suppresses FGFR Gene Expression while Pomalidomide Dampens FGFR2 Activity. Chemistry Research in Toxicology, 32(4), 589-602. https://doi.org/10.1021/acs. chemrestox.8b00286

  31. Trott, O. & Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31, 455-461. https://doi. org/10.1002/jcc.21334

  32. WHO. World Health Organization (2019). Cancer, Available at https://www.who.int/cancer/en/.

  33. Xie, L., Cui, J., Qian, X., Xu, Y., Liu, J. & Xu, R. (2011). 5-Non-amino aromatic substituted naphthalimides as potential anti-tumor agents: synthesis via suzuki reaction, anti-proliferative activity, and DNA-binding behavior. Bioorganic & Medicinal Chemistry, 19, 961-967. https:// doi.org/10.1016/j.bmc.2010.11.055

  34. Yu, N. & Wang, M. (2008). Anticancer drug discovery target ing DNA hyper methylation. Current Medicinal Chemistry, 15, 1350-1375. https://doi. org/10.2174/092986708784567653

  35. Zahran, M. A. H., Abdin, Y. G., Osman, A. M. A., Gamal-Eldeen, A. M., Talaat, R. M. & Pedersen, E. B. (2014). Synthesis and Evaluation of Thalidomide and Phthalimide Esters as Antitumor Agents. Archiv der Pharmazie, 347, 642-649. https://doi.org/10.1002/ardp.201400073




2020     |     www.medigraphic.com